参考文献/References:
[1] Calinescu AA, Kamran N, Baker G, et al. Overview of cu-
rrent immunotherapeutic strategies for glioma [J]. Immuno-
therapy, 2015, 7(10): 1073-1104.
[2] Wong AJ, Ruppert JM, Bigner SH, et al. Structural altera-
tions of the epidermal growth factor receptor gene in human
gliomas [J]. Proc Natl Acad Sci USA, 1992, 89(7): 2965-
2969.
[3] Antonyak M, AMoscatello DK, Wong AJ. Constitutive acti-
vation of c-Jun N-terminal kinase by a mutant epidermal
growth factor receptor [J]. J Biol Chem, 1998, 273(5):
2817-2822.
[4] Sampson JH, Archer GE, Mitchell DA, et al. An epidermal
growth factor receptor variant Ⅲ-targeted vaccine is safe
and immunogenic in patients with glioblastoma multiforme
[J]. Mol Cancer Ther, 2009, 8(10): 2773-2779.
[5] Heimberger AB, Bhussain SF, Aldape K, et al. Tumor-
specific peptide vaccination in newly-diagnosed patients
with GBM [J]. J Clin Oncol, 2006, 24 (18 Suppl): 2529.
[6] Liau LMP, Rins RM, Kiertscher SME, et al. Dendritic cell
vaccination in glioblastoma patients induces systemic and
intracranial T-cell responses modulated by the local central
nervous system tumor microenvironment [J]. Clin Cancer
Res, 2005, 11(15): 5515-5525.
[7] Dutoit V, Herold-Mende C, Hilf N, et al. Exploiting the
glioblastoma peptidome to discover novel tumour-associated
antigens for immunotherapy [J]. Brain, 2012, 135(4): 1042-
1054.
[8] Phillips HSK, harbanda S, Chen R, et al. Molecular sub-
classes of high-grade glioma predict prognosis, delineate a
pattern of disease progression, and resemble stages in
neurogenesis [J]. Cancer Cell, 2006, 9(3): 157-173.
[9] Saikali S, Avril T, Collet B, et al. Expression of nine tumour
antigens in a series of human glioblastoma multiforme:
interest of EGFRvIII, IL-13Rα2, gp100 and TRP-2 for
immunotherapy [J]. J Neurooncol, 2007, 81(2): 139-148.
[10] Liu G, Ying HZ, eng G, et al. HER-2, gp100 and MAGE-1
are expressed in human glioblastoma and recognized by
cytotoxic T cells [J]. Cancer Res, 2004, 64(14): 4980-4986.
[11] Carter T, Shaw H, Cohn-Brown D, et al. Ipilimumab and
Bevacizumab in Glioblastoma [J]. Clin Oncol(R Coll Radiol),
2016, 28(10): 622-626.
[12] Salmggi A, Eoli MF, rigerio S, et al. Intracavitary VEGF,
bFGF, IL-8, IL-12 levels in primary and recurrent malig-
nant glioma [J]. Neurooncol, 2003, 62(3): 297-303.
[13] Ferrars N. Vascular endothelial growth factor: basic science
and clinical progress [J]. Endocr Rev, 2004, 25(4): 581-
611.
[14] Friedman HSP, radoa MD, Wen PY, et al. Bevacizumab
alone and in combination with irinotecan in recurrent
glioblastoma [J]. J Clin Oncol, 2009, 27(28): 4733-4740.
[15] Kreisl TN, KimL, Moore K, et al. Phase 2 trial of single-
agent bevacizumab followed by bevacizumab plus irinotocan
at tumor progress in recurrent glioblastoma [J]. J Clin Oncol,
2009, 27(5): 740-745.
[16] Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation
improves expansion and persistence of chimeric antigen
receptor-modified T cells in lymphoma patients [J]. Clin
Invast, 2011, 121(6): 1822-1826.
[17] Choi BD, Suryadevara CM, Gedeon PC, et al. Intracerebral
delivery of a third generation EGFRvⅢ-specific chimeric
antigen receptor is efficacious against human glioma [J].
Clin Neurosci, 2014, 21: 189-190.
[18] Sampson JH, Choi BDS, anchez-Perez L, et al. EGFRvⅢ
mCAR-modified T cell therapy cures mice with established
intracerebral glioma and generates host immunity against
tumor-antigen loss [J]. Clin Cancer Res, 2014, 20: 972-
984.
相似文献/References:
[1]陈正和 陈忠平.高级别胶质瘤的治疗现状及思考[J].中国临床神经外科杂志,2016,(06):350.[doi:10.13798/j.issn.1009-153X.2016.06.010]
[2]袁凡恩 综述 陈谦学 审校.胶质瘤干细胞的研究进展[J].中国临床神经外科杂志,2016,(08):508.[doi:10.13798/j.issn.1009-153X.2016.08.025]
[3]杨 坤 陈谦学.嵌合抗原受体T细胞治疗胶质母细胞瘤的进展[J].中国临床神经外科杂志,2021,26(06):477.[doi:10.13798/j.issn.1009-153X.2021.06.024]
[4]刘斌超 林志国.CD70在脑胶质瘤中的研究现状[J].中国临床神经外科杂志,2022,27(03):229.[doi:10.13798/j.issn.1009-153X.2022.03.026]
[5]郭晓鹏,王裕,马文斌.脑室播散型复发性胶质母细胞瘤放疗联合靶向治疗及免疫治疗后存活2.5年1例报道并文献复习[J].中国临床神经外科杂志,2024,29(12):720.[doi:10.13798/j.issn.1009-153X.2024.12.004]
GUO Xiao-peng,WANG Yu,MA Wen-bin.Radiotherapy combined with targeted therapy and immunotherapy for ventricular disseminated recurrent glioblastoma surviving for 2.5 years: a case report and literature review[J].,2024,29(07):720.[doi:10.13798/j.issn.1009-153X.2024.12.004]